Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Stock-Based Compensation (SBC) by Year
Stock-Based Compensation (SBC) — Total Pre-Tax Expense ($M) ($M)
Amgen Stock-Based Compensation (SBC): $494M in FY2025, down 6.8% from a year earlier.
Latest, FY2025
494
Period ended Dec 31, 2025
Change on a year earlier
-6.8%
530 in FY2024
History
11 years
Since FY2015
Sources
8
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Stock-Based Compensation Note (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Stock-Based Compensation (SBC) — Total Pre-Tax Expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 494 | -6.8% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 530 | +23.0% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 431 | +7.5% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 401 | +17.6% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 341 | +3.3% | Form 10-K (filed 2024-02-14) ↗ |
| FY2020 | Dec 31, 2020 | 330 | +7.1% | Form 10-K (filed 2023-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 308 | -1.0% | Form 10-K (filed 2022-02-16) ↗ |
| FY2018 | Dec 31, 2018 | 311 | -5.5% | Form 10-K (filed 2021-02-09) ↗ |
| FY2017 | Dec 31, 2017 | 329 | +5.8% | Form 10-K (filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 311 | -3.4% | Form 10-K (filed 2019-02-13) ↗ |
| FY2015 | Dec 31, 2015 | 322 | – | Form 10-K (filed 2018-02-13) ↗ |
Breakdown
What makes up stock-Based Compensation (SBC)
- SBC Income Tax Benefit ($M)106 · FY2025
- SBC Expense, Net of Tax ($M)388 · FY2025
- SBC Expense by Award Type — Restricted Stock Units (RSUs) ($M)333 · FY2025
- SBC Expense by Award Type — Performance Units (PSUs) ($M)112 · FY2025
- SBC Expense by Award Type — Stock Options ($M)49 · FY2025
- Unrecognized SBC Compensation Cost — Total ($M)537 · FY2025
- Shares Available for Future Grant Under Equity Incentive Plan (M shares)35 · FY2025
- Stock Options — Shares Outstanding at Period End (M shares)6.10 · FY2025
- Restricted Stock Units (RSUs) — Nonvested Shares Outstanding (M shares)3.70 · FY2025
- Performance Units (PSUs) — Nonvested Units Outstanding (M shares)1.20 · FY2025
Cite this data
StockData. (2026). Amgen Stock-Based Compensation (SBC) ($M), annual FY2015–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/sbc-exp-tot
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.